Table 4.
Number of MDR TB patients who had a persistent side effect at the end of MDR TB treatment, 2012–2016. (N = 13).
| Side effect | Number (%) |
|---|---|
| Peripheral neuropathy | 3 (23%) |
| Renal dysfunctiona | 3 (23%) |
| Hearing loss | 2 (15%) |
| Vision change/loss | 1 (8%) |
| Tinnitus | 0 (0%) |
| Vestibular dysfunction | 0 (0%) |
| Liver toxicityb | 0 (0%) |
| Other | 2 (15%) |
| Tremor | 1 (50%) |
| Depression | 1 (50%) |
MDR = multidrug resistant, i.e., resistant to at least isoniazid and rifampin.
a
Renal dysfunction was defined as a change in baseline renal function such that a patient has transitioned from baseline kidney stage to another, higher stage.
b
Liver toxicity was defined as liver transaminases exceeding three times the upper limit of normal with associated symptoms, or five times the upper limit of normal if the patient is asymptomatic.